Tags : Dr. Reddy

M&A

Glenmark to Divest Select Anti-Allergy Brands to Dr. Reddy’s in

Shots: Dr. Reddy to acquire Glenmark’s brands Momat Rino (for Russia, Kazakhstan, and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan & Uzbekistan), Glenspray, and Glenspray Active (for Ukraine) along-with rights to the trademarks, dossiers, and patents for the mentioned territories The acquired products will further strengthen Dr. Reddy’s presence in the anti-allergy […]Read More

Insights+

Insights+ Key Biosimilars Events of September 2019

Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the […]Read More

Biosimilars

Dr. Reddy Plans the Onset of P-III trial for DRL_RI

Shots: The P-III trial involves assessing of DRL_RI vs Roche’s MabThera (rituximab) in 284 patients including 26 Koreans, with stage II-IV, CD20 positive, and follicular lymphoma previously treated have low tumor burden, evaluating its efficacy, safety, and immunogenicity Dr. Reddy’s plan to evaluate DRL_RI in Korea while Paraxel to provide clinical research services and Korea’s […]Read More

M&A

Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy’s

Shots: Encore through its subsidiary Promius Pharma, has acquired US commercialization rights for Sernivo spray (betamethasone dipropionate), Trianex (Triamcinolone Acetonide Ointment, USP) and Promiseb from Dr. Reddy The focus of the acquisition is to expand Encore’s portfolio of dermatology products for the treatment of skin diseases such as psoriasis, atopic dermatitis and acne Sernivo (betamethasone […]Read More

Biosimilars Pharma

Dr. Reddy Launched Hervycta (biosimilar Trastuzumab) in India

Shots: Hervycta (biosimilar Trastuzumab) indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer)  Marketed as 150mg and 440mg multiple dose vials  As per Dr. Reddy, it has four biosimilars commercialized in India Click here to read full press release/ article | Ref: Dr. Reddy Laboratories | Image: Dr […]Read More